

Application for the following position in the EHRA Board:

**Secretary**



## 1. Your Identity

Title: **MD PhD FEHRA.**

Family Name(s): **Merino**

First Name(s): **Jose Luis**

Birth Date: **September 22nd, 1963**

Type of address: ☒ Business ☐ Home

Institute/Organisation: **University Hospital La Paz**

Department: **Cardiology. Arrhythmia and Robotic EP Unit**

Address: **P. Castellana, 261**

Post Code/Zip: **28046**

City: **Madrid (Spain)**



## 2. General Curriculum Vitae (300 words max)

### Present position:

- Director of the Arrhythmia and EP Robotic Unit at La Paz University Hospital, Madrid, Spain
- Electrophysiology Specialist at Ruber-JB and Nisa-PA Hospitals, Madrid.
- Assistant professor of cardiology in the European and Francisco Vitoria Universities, Madrid.

### Education:

- MD (1988) and PhD degrees (1993, doctoral thesis) at Complutense University, Madrid.
- Residency in Internal Medicine and Cardiology at La Paz University Hospital (1989-1993).
- Further training in Cardiac Arrhythmias and Electrophysiology as a fellow at Gregorio Marañón (Spain, 1993-1995), the Boston Children's (USA, 1993), and London St George's (UK, 1994) hospitals.
- Certified (log book and exam) by the Spanish Society of Cardiology as Interventional Electrophysiologist (2004)

### Scientific Societies Involvement (see section 3):

- Fellow of EHRA (FEHRA)
- Honorary member of the Argentinian Society of Cardiology and regular lecturer in major Latinoamerican scientific events.

### Research:

- Main research interest:
  1. Electrophysiology and ablation of atrial and ventricular arrhythmias, with special interest on bundle-branch re-entry, left atrial flutter, ischemic VT and AF.
  2. 3D-electroanatomical mapping systems.
  3. Remote navigation systems (Magnetecs and Amigo systems).
  4. ICDs.
  5. New antiarrhythmic and anticoagulants.
- More than 150 articles published in indexed journals, such as the New England Journal of Medicine, Lancet, European Heart Journal, or Circulation.
- Editor of 12 books and author of more than 40 books chapters on HR disorders including participation in the ESC Textbook of Cardiovascular Medicine (3rd ed)
- More than 400 contributions as congress abstracts in major cardiology and HR congresses.
- Steering committee member (5), national coordinator and PI (>25) of international randomized multicentre trials.
- Director of 4 PhD thesis

### Other:

- External advisor of European Medical Agency (EMA).
- Director of several educational courses including the EHRA EP Exam preparatory course (3 Ed) and the "AF Madrid" Symposium (6 eds).



### 3. Previous experience(s) within:

#### European Heart Rhythm Association Board (EHRA)

- Chairperson of the Education Committee. (2015-present)
- Member of the Selection Committee. (2017-present)
- Member of the Scientific Committee of the EHRA-Europace Congresses 2007, 2009, 2011, 2018, 2019.
- Chairperson of the Training Fellowships Committee. (2011-2015)
- EHRA White Book Coordinator (2011)
- Member of the National Societies Committee. (2009-2011)
- Member of the Scientific Initiatives Committee. (2007-2009)
- Main author of the EHRA Core Curriculum for the Heart Rhythm Specialist (2009)
- Chairperson of the Certification Committee on EP and PM/ICDs. (2005-2007).
- Co-Chairperson of the Task Force on EP and Pacing Certification. (2003-2005).

#### European Society of Cardiology (ESC)

- Member of the ESC Task Force on Live Events (2018-present)
- Member of the ESC Education Committee (2016-2018)
- Member of the Task force for Subspecialty Accreditation within Cardiology of the EBSC. (2003-2007)

#### Spanish Society of Cardiology

- Chairperson of the Accreditation Committee on Electrophysiology. (2007-2010).
- President of the Working Group on Electrophysiology & Arrhythmias. (2003-2006).

### 4. Why are you interested in joining EHRA Board (150 words max)?

I have been always interested in improving things to our profession. This is why, together with others, I initiated, first in my own country (Spanish Certification System, ablation registry, annual congress, etc) and later at the European level (EHRA certification, EHRA Core-curriculum for the HR specialist, EHRA Network of Centres, etc.), initiatives to promote and improve our profession and which eventually result in benefits to our patients. At the same time, I believe that union makes strength and have always seek to promote ways to improve national collaboration in Europe and the ESC area. I have to say that I feel granted to see all the achievements EHRA have made in the recent past and for being given the privilege and opportunity to contribute to it together with so many colleagues (many of them now close friends). Much have been done but still we need to keep improving.



## 5. How will you coordinate your EHRA appointment with your daily clinical/research workload?

I have been heavily involved in EHRA for many years in different positions. Therefore, I am already used to devote a significant part of my time to EHRA. This has also given me significant experience to deal with the duties and tasks of the EHRA secretary. This may also result in a time-saving way to deal with new tasks and roles since I am familiar with procedures and how things are managed at EHRA and the Heart house. Finally, I have recently asked for a 50% reduction of my clinical duties in order to have more time for research and my EHRA tasks and my hospital has recently contracted a new staff to cover this time of my practice.

## 6. Please list your conflict of interest

- Direct personal payments (speaker fees, honoraria, advisory board fees, consultancy, investigator...)
- Payments to your institution (speaker fees, honoraria, advisory board fees, consultancy, investigator...)
- Receipts of royalties for intellectual property
- Research funding (departmental or institutional)
- Research funding (personal)
- Nothing to declare

✓ Company (one company):

✓ Product or therapeutic area:

☐ <10 K€/year ☐ 10-50 K€/year ☐ 50-100 K€/year ☐ >100 >K€/year

✓ Company (one company):

✓ Product or therapeutic area:

☐ <10 K€/year ☐ 10-50 K€/year ☐ 50-100 K€/year ☐ >100 >K€/year

### Position of influence declaration:

- Direct substantial shareholding or direct financial interest in healthcare, media, education companies or companies in relationship (suppliers or in competition with ESC or in contradiction with ESC mission)
- Employment in healthcare institution (part time or full time)
- Membership or affiliation to political/pressure group associations related to the field of cardiology
- Any potential interest to be declared related to the current position to be held
- Nothing to declare





**EHRA**

European Heart  
Rhythm Association

**1 - Financial Declaration**

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.

Company: Cardiome.

Product: Vernakalant

Income: <10 k€/year

Company: Sanofi.

Product: Dronedarone

Income: <10 k€/year

Company: Abbott

Product: Atrial fibrillation

Income: 10-50 k€/year

Company: Boston Scientific

Product: Defibrillators

Income: 10-50 k€/year

Company: Biotronik

Product: Defibrillators

Income: 10-50 k€/year

Company: Daiichi Sankyo

Product: Edoxaban

Income: <10 k€/year

Company: Medtronic

Product: Defibrillators, Holter

Income: <10 k€/year

Company: Sorin Group

Product: Defibrillators

Income: <10 k€/year

Company: Bayer

Product: Atrial fibrillation

Income: <10 k€/year

Company: Biosense Webster

Product: Catheter ablation

Income: <10 k€/year

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.

Nothing To Declare

C - Receipt of royalties for intellectual property.

Nothing To Declare



**ESC**

European Society  
of Cardiology



**EHRA**

European Heart  
Rhythm Association

D - Research funding (departmental or institutional) from healthcare industry.

Company: Boston Scientific

Product: Defibrillators

Income: <10 k€/year

Company: Medtronic

Product: Defibrillators

Income: 10-50 k€/year

Company: Pfizer

Product: Atrial fibrillation

Income: 10-50 k€/year

Company: Daiichi Sankyo

Product: Atrial fibrillation

Income: 10-50 k€/year

Does any of your declared research funding to your institution impact your remuneration?

No

E - Research funding (personal).

Company: Daiichi Sankyo

Product: Edoxaban

Income: 10-50 k€/year

Company: Boehringer-Ingelheim

Product: Dabigatran in AF ablation

Income: <10 k€/year

**2 - Other Positions of Influence**

2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.

Nothing to declare

2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.

Nothing to declare

2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.



**ESC**

European Society  
of Cardiology